Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
BUPRENORPHINE HYDROCHLORIDE (UNII: 56W8MW3EN1) (BUPRENORPHINE - UNII:40D3SCR4GZ), NALOXONE HYDROCHLORIDE DIHYDRATE (UNII: 5Q187997EE) (NALOXONE - UNII:36B82AMQ7N)
Bryant Ranch Prepack
BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE 8 mg
SUBLINGUAL
PRESCRIPTION DRUG
Buprenorphine and Naloxone Sublingual Tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. Buprenorphine and Naloxone Sublingual Tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions (5.9)] . Risk Summary The data on use of buprenorphine, one of the active ingredients in Buprenorphine and Naloxone Sublingual Tablets, in pregnancy, are limited; however, these data do not indicate an increased risk of major malformations specifically due to buprenorphine exposure. There are limited data from randomized clinical trials in women maintained on buprenorphine that were not designed appropriately to assess the risk of major malformations [see Data] . Observational studies have reported on con
Product: 63629-5074 Product: 63629-7269 NDC: 63629-7269-1 30 TABLET in a BOTTLE NDC: 63629-5074-1 30 TABLET in a BOTTLE
Abbreviated New Drug Application
BUPRENORPHINE HCL AND NALOXONE HCL- BUPRENORPHINE AND NALOXONE TABLET Bryant Ranch Prepack ---------- MEDICATION GUIDE BUPRENORPHINE (bue” pre nor’ feen) AND NALOXONE (nal ox’ one) SUBLINGUAL TABLETS (CIII) IMPORTANT: Keep buprenorphine and naloxone sublingual tablets in a secure place away from children. Accidental use by a child is a medical emergency and can result in death. If a child accidentally uses buprenorphine and naloxone sublingual tablets, get emergency help right away. Read this Medication Guide that comes with buprenorphine and naloxone sublingual tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor. Talk to your doctor or pharmacist if you have questions about buprenorphine and naloxone sublingual tablets. Share the important information in this Medication Guide with members of your household. What is the most important information I should know about buprenorphine and naloxone sublingual tablets? • Buprenorphine is a medicine in buprenorphine and naloxone sublingual tablets that can cause serious and life-threatening problems, especially if you take or use certain other medicines or drugs. Call your healthcare provider right away or get emergency help if you: • feel faint or dizzy • have mental changes such as confusion • have slower breathing than you normally have • have severe sleepiness • have blurred vision • have problems with coordination • have slurred speech • cannot think well or clearly • have slowed reflexes • have a high body temperature • feel agitated • have stiff muscles • have trouble walking • Do not switch from buprenorphine and naloxone sublingual tablets to other medicines that contain buprenorphine without talking with your doctor. The amount of buprenorphine in a dose of buprenorphine and naloxone sublingual tablets is not the same as the amount of buprenorphine in other medicines that contain buprenorphine. Your doctor will Izlasiet visu dokumentu
BUPRENORPHINE HCL AND NALOXONE HCL- BUPRENORPHINE AND NALOXONE TABLET BRYANT RANCH PREPACK ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS. BUPRENORPHINE AND NALOXONE SUBLINGUAL TABLETS, FOR SUBLINGUAL ADMINISTRATION CIII INITIAL U.S. APPROVAL: 2002 RECENT MAJOR CHANGES Warnings and Precautions (5.2) 10/2019 INDICATIONS AND USAGE Buprenorphine and Naloxone Sublingual Tablets contain buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist, and is indicated for the maintenance treatment of opioid dependence. (1) Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support. (1) DOSAGE AND ADMINISTRATION Prescription use of this product is limited under the Drug Addiction Treatment Act. (2.1) Administer Buprenorphine and Naloxone Sublingual Tablets sublingually as a single daily dose. (2.2) To avoid precipitating withdrawal, induction with Buprenorphine Sublingual Tablets should be undertaken when objective and clear signs of withdrawal are evident. After induction, doses of Buprenorphine and Naloxone Sublingual Tablets should be progressively adjusted to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms. (2.3) The recommended target dosage of Buprenorphine and Naloxone Sublingual Tablets for maintenance is 16 mg/4 mg. (2.3) Administer Buprenorphine and Naloxone Sublingual Tablets as directed in the Full Prescribing Information. (2.3, 2.4) When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. (2.7) DOSAGE FORMS AND STRENGTHS Sublingual tablet: 2 mg buprenorphine with 0.5 mg naloxone and 8 mg buprenorphine with 2 mg naloxone. (3) CONTRAINDICATIONS Hypersensitivity to buprenorphine or naloxone. (4) WARNINGS AND PRECAUT Izlasiet visu dokumentu